Urcosimod Success

OKYO’s previous phase 2 data showed statistically significant improvements in several endpoints for neuropathic corneal pain patients, reinforcing the potential of urcosimod. The confirmation of the primary endpoint and the alignment on key trial components position the company to advance its novel ocular‑disease–focused pipeline.